Irinotecan liposome is approved by the USFDA for first-line treatment of metastatic pancreatic adenocarcinoma
Irinotecan liposome is approved by the USFDA for first-line treatment of metastatic pancreatic adenocarcinoma
Irinotecan liposome is approved by the USFDA for first-line treatment of metastatic pancreatic adenocarcinoma
Irinotecan liposome is approved by the USFDA for first-line treatment of metastatic pancreatic adenocarcinoma